Immunochemicals: Market Research Report
This report analyzes the worldwide markets for Immunochemicals in US$ Thousand by the following Product Types: Catalog Antibodies, and Custom Antibodies.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.
Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
Company profiles are primarily based on public domain information including company URLs. The report profiles 116 companies including many key and niche players such as -
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024.
Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
Company profiles are primarily based on public domain information including company URLs. The report profiles 116 companies including many key and niche players such as -
- Abcam Plc
- Agilent Research Laboratories
- Beckman Coulter GmbH
- Biolegend, Inc.
- Bio-Rad Laboratories, Inc.
- Cell Signaling Technology, Inc.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Immunochemicals – A Prelude
Research Antibodies Market: Critical Role in Drug Discovery and Research
Key Factors Influencing Purchasing Decisions
Citations: One of the Key Factors Driving Research Antibodies’ Purchase
The US Dominates the Global Immunochemicals Market
Emerging Markets Offer Huge Potential
Catalog Antibodies – The Largest Market Segment
Custom Antibodies: Finding Favor in Research Applications
Primary Antibodies Dominate the Market
Competitive Scenario
2. MARKET TRENDS AND GROWTH DRIVERS
Increasing Research Funding Bolsters Market Growth
Chinese Market to Become the Largest Investor in Basic Research
Cancer Research Drives the Global Immunochemicals Market
Cancer Ranks Among the Top Ten Causes of Death Worldwide
‘Reproducibility Crisis’ of Antibodies - A Major Cause of Concern
Proper Validation of Antibodies – Vendor Do their Part
New Technologies for Antibodies Validation
Personalized Medicine Offers New Growth Avenues
Rabbit Monoclonal Antibodies Score over Other Animal Antibodies
Researchers Prefer Commercial Research to Academic Research
Increasing Collaborations between Industry and Academia
3. AN INTRODUCTION TO IMMUNOCHEMICALS
4. ANTIBODIES – A PRIMER
Introduction to Antibodies
Antibodies in Research Applications
Monoclonal Antibodies
Properties
Applications
Monoclonal Antibodies for Cancer Treatment
Various Types of mAbs Used in Cancer Treatment
Polyclonal Antibodies
Production Process
Properties
Applications
Conjugate Antibodies
Antibody Drug Conjugate Technology – An Overview
ADC Technology – Its Evolution and Developmental Challenges
Antibody Technology – Enables Better Specificity and Batch Consistency (2016)
ABfinity Technology
Linker Technology
Challenges
Pre-requisites of an Effective ADC
ADC Manufacturing – The Need for Outsourcing
Target Antigen Selection Critical in Developing Successful ADCs
Forms of Tumor-Related Antigens
Availability of ADCs
Antibody-Drug Conjugates (ADCs) in Development
ADC Market: An Insight into the Future
5. RECENT INDUSTRY ACTIVITY
MedImmune & Sanofi Pasteur Enters Agreement to Develop & Commercialize MEDI8897
TRIANNI Signs License Agreement with Fred Hutch
ImmunoPrecise Introduces New Research Initiative
Green Mountain Signs Agreement with ILRI
Abcam Extends License & Supply Agreement with Horizon Discovery
Shire Plc. Signs License Agreement with Novimmune S. A to Broaden Monoclonal Antibody Research Platform
Morphotek Partners with Johns Hopkins University to Research and Develop of Biological Therapies
Rockland Announces Availability of New Melanoma Cell Lines for Research
Kymab and MD Anderson Team Up for R&D in Immuno-Oncology
Achaogen and Crystal Bioscience to Develop Multiple Targeted Antibodies
Zymeworks Announces the Merger and Acquisition of Kairos Therapeutics
Merck Acquires Sigma-Aldrich
Abzena Acquires The Chemistry Research Solution LLC
Abcam Enters into a Definitive Agreement to Acquire AxioMx.
Igenica Biotherapeutics Signs Deal with MedImmune
Regeneron Pharma Signs Deal with The Experimental Therapeutics Institute
Invenra Partners with Oxford BioTherapeutics
Bio-Rad Labs Releases PrecisonAb Antibodies for use in Western Blotting
Cell Signaling Technology Releases 6 New Monoclonal Antibodies
Abcam Launches an Anti-PD-L1 Primary Antibody
6. FOCUS ON SELECT GLOBAL PLAYERS
Abcam Plc. (UK)
Agilent Research Laboratories (USA)
Beckman Coulter GmbH (USA)
Biolegend, Inc. (USA)
Bio-Rad Laboratories, Inc. (USA)
Cell Signaling Technology, Inc. (USA)
GenScript Biotech Corporation
PerkinElmer, Inc. (USA)
Rockland Immunochemicals, Inc. (USA)
Santa Cruz Biotechnology, Inc. (USA)
Merck (Sigma-Aldrich Corporation) (USA)
Thermo Fisher Scientific Inc. (USA)
7. GLOBAL MARKET PERSPECTIVE
III. MARKET
1. THE UNITED STATES
A. Market Analysis
United States: The Largest Region for Immunochemicals Worldwide
Increase in NIH Funding to Support Basic Research
Increase in Cancer Incidence Drives Oncology Research
Strategic Corporate Developments
Select Key Players
B. Market Analytics
2. CANADA
A. Market Analysis
Cancer Incidence in Canada
Strategic Corporate Developments
B. Market Analytics
3. JAPAN
A. Market Analysis
B. Market Analytics
4. EUROPE
A. Market Analysis
Current and Future Analysis
Research Funding in Europe
Cancer Statistics
Strategic Corporate Developments
Select Key Player
B. Market Analytics
5. ASIA-PACIFIC
A. Market Analysis
Asia-Pacific – The Fastest Growing Market for Immunochemicals Globally
Cancer Research: A Focal Area
B. Market Analytics
5A. CHINA
A. Market Analysis
Increased Investments in Basic Research
Rising Incidence of Cancer & Age-Related Conditions: Potential Opportunity
B. Market Analytics
5B. REST OF ASIA-PACIFIC
Market Analysis
6. LATIN AMERICA
Market Analysis
7. REST OF WORLD
A. Market Analysis
Strategic Corporate Development
B. Market Analytics
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 116 (including Divisions/Subsidiaries - 124)
The United States (75)
Canada (5)
Japan (2)
Europe (37)
France (4)
Germany (7)
The United Kingdom (10)
Rest of Europe (16)
Asia-Pacific (Excluding Japan) (5)
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Immunochemicals – A Prelude
Research Antibodies Market: Critical Role in Drug Discovery and Research
Table 1. Antibody-based Application by Type: 2017 (includes corresponding Graph/Chart)
Key Factors Influencing Purchasing Decisions
Table 2. Research and Development Budget Growth of Top Pharma Companies: 2013-2018 (includes corresponding Graph/Chart)
Citations: One of the Key Factors Driving Research Antibodies’ Purchase
The US Dominates the Global Immunochemicals Market
Emerging Markets Offer Huge Potential
Catalog Antibodies – The Largest Market Segment
Custom Antibodies: Finding Favor in Research Applications
Primary Antibodies Dominate the Market
Competitive Scenario
Table 3. Global Primary Research Antibodies Market by Leading Players: Market Share for the year 2016 (includes corresponding Graph/Chart)
2. MARKET TRENDS AND GROWTH DRIVERS
Increasing Research Funding Bolsters Market Growth
Table 4. NIH Budget Appropriations for Financial Years: 2007 to 2017 (includes corresponding Graph/Chart)
Chinese Market to Become the Largest Investor in Basic Research
Cancer Research Drives the Global Immunochemicals Market
Table 5. Growing Burden of Cancer Worldwide - Number of New Cancer Cases and Cancer-Related Deaths for the Year 2012 and 2030 (includes corresponding Graph/Chart)
Cancer Ranks Among the Top Ten Causes of Death Worldwide
Table 6. Common Cause of Cancer Deaths Worldwide - Number of Deaths due to Select Types of Cancer for 2015 (includes corresponding Graph/Chart)
Table 7. New Cancer Cases in the World by Affected Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
‘Reproducibility Crisis’ of Antibodies - A Major Cause of Concern
Proper Validation of Antibodies – Vendor Do their Part
New Technologies for Antibodies Validation
Personalized Medicine Offers New Growth Avenues
Rabbit Monoclonal Antibodies Score over Other Animal Antibodies
Researchers Prefer Commercial Research to Academic Research
Increasing Collaborations between Industry and Academia
3. AN INTRODUCTION TO IMMUNOCHEMICALS
4. ANTIBODIES – A PRIMER
Introduction to Antibodies
Antibodies in Research Applications
Monoclonal Antibodies
Properties
Applications
Monoclonal Antibodies for Cancer Treatment
Various Types of mAbs Used in Cancer Treatment
Polyclonal Antibodies
Production Process
Properties
Applications
Conjugate Antibodies
Antibody Drug Conjugate Technology – An Overview
ADC Technology – Its Evolution and Developmental Challenges
Antibody Technology – Enables Better Specificity and Batch Consistency (2016)
ABfinity Technology
Linker Technology
Challenges
Pre-requisites of an Effective ADC
ADC Manufacturing – The Need for Outsourcing
Target Antigen Selection Critical in Developing Successful ADCs
Forms of Tumor-Related Antigens
Availability of ADCs
Antibody-Drug Conjugates (ADCs) in Development
ADC Market: An Insight into the Future
5. RECENT INDUSTRY ACTIVITY
MedImmune & Sanofi Pasteur Enters Agreement to Develop & Commercialize MEDI8897
TRIANNI Signs License Agreement with Fred Hutch
ImmunoPrecise Introduces New Research Initiative
Green Mountain Signs Agreement with ILRI
Abcam Extends License & Supply Agreement with Horizon Discovery
Shire Plc. Signs License Agreement with Novimmune S. A to Broaden Monoclonal Antibody Research Platform
Morphotek Partners with Johns Hopkins University to Research and Develop of Biological Therapies
Rockland Announces Availability of New Melanoma Cell Lines for Research
Kymab and MD Anderson Team Up for R&D in Immuno-Oncology
Achaogen and Crystal Bioscience to Develop Multiple Targeted Antibodies
Zymeworks Announces the Merger and Acquisition of Kairos Therapeutics
Merck Acquires Sigma-Aldrich
Abzena Acquires The Chemistry Research Solution LLC
Abcam Enters into a Definitive Agreement to Acquire AxioMx.
Igenica Biotherapeutics Signs Deal with MedImmune
Regeneron Pharma Signs Deal with The Experimental Therapeutics Institute
Invenra Partners with Oxford BioTherapeutics
Bio-Rad Labs Releases PrecisonAb Antibodies for use in Western Blotting
Cell Signaling Technology Releases 6 New Monoclonal Antibodies
Abcam Launches an Anti-PD-L1 Primary Antibody
6. FOCUS ON SELECT GLOBAL PLAYERS
Abcam Plc. (UK)
Agilent Research Laboratories (USA)
Beckman Coulter GmbH (USA)
Biolegend, Inc. (USA)
Bio-Rad Laboratories, Inc. (USA)
Cell Signaling Technology, Inc. (USA)
GenScript Biotech Corporation
PerkinElmer, Inc. (USA)
Rockland Immunochemicals, Inc. (USA)
Santa Cruz Biotechnology, Inc. (USA)
Merck (Sigma-Aldrich Corporation) (USA)
Thermo Fisher Scientific Inc. (USA)
7. GLOBAL MARKET PERSPECTIVE
Table 8. World Recent Past, Current & Future Analysis for Immunochemicals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 9. World Historic Review for Immunochemicals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 10. World 14-Year Perspective for Immunochemicals by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 11. World Recent Past, Current & Future Analysis for Catalog Antibodies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 12. World Historic Review for Catalog Antibodies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 13. World 14-Year Perspective for Catalog Antibodies by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 14. World Recent Past, Current & Future Analysis for Custom Antibodies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 15. World Historic Review for Custom Antibodies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 16. World 14-Year Perspective for Custom Antibodies by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A. Market Analysis
United States: The Largest Region for Immunochemicals Worldwide
Increase in NIH Funding to Support Basic Research
Table 17. NIH Appropriations for Financial Years: 2007 To 2017 (includes corresponding Graph/Chart)
Increase in Cancer Incidence Drives Oncology Research
Table 18. Estimated Number of New Cancer Cases in the US by Gender and Affected Site for 2017 (includes corresponding Graph/Chart)
Table 19. Estimated Number of Cancer-Related Deaths in the US by Gender and Body Site for 2017 (includes corresponding Graph/Chart)
Table 20. Estimated Number of New Cancer Cases in the US by State for 2017 (includes corresponding Graph/Chart)
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Table 21. The US Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 22. The US Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 23. The US 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
2. CANADA
A. Market Analysis
Cancer Incidence in Canada
Table 24. New Cancer Cases (in Thousands) in Canada by Gender for 2015 and 2016 (includes corresponding Graph/Chart)
Table 25. New Cancer Cases in Canada by Gender and Affected Site for 2016 (includes corresponding Graph/Chart)
Strategic Corporate Developments
B. Market Analytics
Table 26. Canadian Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 27. Canadian Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 28. Canadian 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
3. JAPAN
A. Market Analysis
Table 29. Cancer Incidence and Number of Cancer-Related Deaths among Japanese Men and Women for 2015 (includes corresponding Graph/Chart)
B. Market Analytics
Table 30. Japanese Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 31. Japanese Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 32. Japanese 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
4. EUROPE
A. Market Analysis
Current and Future Analysis
Research Funding in Europe
Cancer Statistics
Table 33. Number of New Cancer Cases in Europe (2012-2030) (in Million) (includes corresponding Graph/Chart)
Strategic Corporate Developments
Select Key Player
B. Market Analytics
Table 34. European Recent Past, Current & Future Analysis for Immunochemicals by Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 35. European Historic Review for Immunochemicals by Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 36. European 14-Year Perspective for Immunochemicals by Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 37. European Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 38. European Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 39. European 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
5. ASIA-PACIFIC
A. Market Analysis
Asia-Pacific – The Fastest Growing Market for Immunochemicals Globally
Cancer Research: A Focal Area
B. Market Analytics
Table 40. Asia-Pacific Recent Past, Current & Future Analysis for Immunochemicals by Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2016 Through 2024 (includes corresponding Graph/Chart)
Table 41. Asia-Pacific Historic Review for Immunochemicals by Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2011 Through 2015 (includes corresponding Graph/Chart)
Table 42. Asia-Pacific 14-Year Perspective for Immunochemicals by Region - Percentage Breakdown of Dollar Sales for China and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
Table 43. Asia-Pacific Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 Through 2024 (includes corresponding Graph/Chart)
Table 44. Asia-Pacific Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 Through 2015 (includes corresponding Graph/Chart)
Table 45. Asia-Pacific 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Dollar Sales for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
5A. CHINA
A. Market Analysis
Increased Investments in Basic Research
Rising Incidence of Cancer & Age-Related Conditions: Potential Opportunity
Table 46. Cancer Statistics in China - New Cancer Cases and Cancer-Related Deaths for 2015
B. Market Analytics
Table 47. Chinese Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 48. Chinese Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 49. Chinese 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
5B. REST OF ASIA-PACIFIC
Market Analysis
Table 50. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 Through 2024 (includes corresponding Graph/Chart)
Table 51. Rest of Asia-Pacific Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 Through 2015 (includes corresponding Graph/Chart)
Table 52. Rest of Asia-Pacific 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
6. LATIN AMERICA
Market Analysis
Table 53. Latin American Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 54. Latin American Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 Through 2015 (includes corresponding Graph/Chart)
Table 55. Latin American 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
7. REST OF WORLD
A. Market Analysis
Strategic Corporate Development
B. Market Analytics
Table 56. Rest of World Recent Past, Current & Future Analysis for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 57. Rest of World Historic Review for Immunochemicals by Type - Catalog Antibodies and Custom Antibodies Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 58. Rest of World 14-Year Perspective for Immunochemicals by Type - Percentage Breakdown of Annual Revenues for Catalog Antibodies and Custom Antibodies Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 116 (including Divisions/Subsidiaries - 124)
The United States (75)
Canada (5)
Japan (2)
Europe (37)
France (4)
Germany (7)
The United Kingdom (10)
Rest of Europe (16)
Asia-Pacific (Excluding Japan) (5)